Ultra-long-term follow-up of renal denervation in patients with resistant hypertension and mild chronic kidney disease

• Published in: Zhōnghuá xīnxuèguănbìng zázhi Vol. 53; no. 10; p. 1119
• Main Authors: Wang, L, Zhang, H, Li, C, Yin, X M, Li, Z Q, He, Q, Sun, X Q, Xia, D C, Kong, D L, Lu, C Z
• Format: Journal Article
• Language: Chinese
• Published: China 24.10.2025
• Subjects: Aged; Antihypertensive Agents - therapeutic use; Blood Pressure; Denervation; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension - surgery; Kidney - innervation; Male; Middle Aged; Renal Insufficiency, Chronic - surgery; Retrospective Studies; Sympathectomy; Treatment Outcome
• ISSN: 0253-3758
• DOI: 10.3760/cma.j.cn112148-20250721-00521

To investigate the ultra-long-term antihypertensive efficacy, safety, major adverse events, and survival benefits of renal denervation (RDN) in patients with resistant hypertension (rHTN) and mild chronic kidney disease (CKD). This real-world, single-center retrospective study enrolled patients with rHTN and mild CKD who underwent RDN at Tianjin First Central Hospital between October 2011 and June 2016. Office blood pressure, home self-measured blood pressure, 24-hour ambulatory blood pressure, serum creatinine, estimated glomerular filtration rate, and urine albumin-to-creatinine ratio were collected at baseline and at 1, 5, and 13 years post-RDN. The total daily defined dose of antihypertensive medications at 13 years post-RDN was recorded, along with endpoint events during follow-up, including cardiovascular death, all-cause death, hospitalization for heart failure, myocardial infarction, and stroke. Patients were stratified according to CKD stage (G1-G2 vs. G3a) and baseline systolic blood pressure (mild-